[Form 4] ARROWHEAD PHARMACEUTICALS, INC. Insider Trading Activity
James C. Hamilton, Chief Medical Officer of Arrowhead Pharmaceuticals (ARWR), reported a sale of 15,000 shares of common stock on 09/12/2025 at $30 per share under a pre-established 10b5-1 trading plan. After the transaction he beneficially owns 232,122 shares, which includes previously reported shares underlying restricted stock units, some of which remain subject to vesting.
The Form 4 discloses the transaction and the reporting person’s relationship to the issuer (Officer and Director). The filing clarifies the sale was pursuant to the trading plan and that a portion of the reported holdings represents unvested restricted stock units.
James C. Hamilton, Chief Medical Officer di Arrowhead Pharmaceuticals (ARWR), ha riferito la vendita di 15.000 azioni ordinarie in data 09/12/2025 al prezzo di $30 per azione, nell’ambito di un piano di trading 10b5-1 predefinito. Dopo la transazione detiene beneficially 232.122 azioni, inclusi azioni già riportate legate a unità di azioni vincolate, alcune delle quali restano soggette a vesting.
Il Form 4 rende nota la transazione e la relazione della persona che segnala con l’emittente (Funzionario e Direttore). Il deposito chiarisce che la vendita è avvenuta secondo il piano di trading e che una parte delle partecipazioni riportate rappresenta unità azionarie vincolate non ancora vestite.
James C. Hamilton, Director Médico de Arrowhead Pharmaceuticals (ARWR), informó la venta de 15,000 acciones ordinarias en la fecha 12/09/2025 a $30 por acción, dentro de un plan de negociación 10b5-1 preestablecido. Tras la operación posee beneficiosamente 232,122 acciones, incluidas las acciones previamente reportadas vinculadas a unidades de acciones restringidas, algunas de las cuales siguen sujetas a vesting.
El Formulario 4 divulga la operación y la relación de la persona reportante con el emisor (Funcionarios y Directivos). La presentación aclara que la venta se realizó de acuerdo con el plan de negociación y que una parte de las participaciones reportadas representa unidades de acciones restringidas no vestidas.
James C. Hamilton, Arrowhead Pharmaceuticals(ARWR)의 최고의료책임자, 15,000주 일반주를 2025년 9월 12일에 $30의 주당가로 미리 설정된 10b5-1 거래계획에 따라 매도했다고 보고했습니다. 거래 후 그는 232,122주를 실질적으로 보유하며, 이는 이전에 보고된 제한주식단위와 관련된 주식을 포함하고, 그 중 일부는 아직 vesting 중입니다.
Form 4는 거래와 공시자의 발행자에 대한 관계(임원 및 이사)를 공개합니다. 공시서는 거래가 거래계획에 따라 이루어졌고 보고된 보유분 중 일부가 아직 vesting 중인 제한주식단위를 나타낸다고 명시합니다.
James C. Hamilton, Directeur médical chez Arrowhead Pharmaceuticals (ARWR), a signalé la vente de 15 000 actions ordinaires le 12/09/2025 à 30 $ par action dans le cadre d’un plan de négociation 10b5-1 préétabli. Suite à la transaction, il détient avantageusement 232 122 actions, ce qui inclut des actions déjà signalées liées à des unités d’actions restreintes, dont certaines restent soumises à vesting.
Le Formulaire 4 divulgue la transaction et la relation du déclarant avec l’émetteur (Dirigeant et Administrateur). Le dépôt précise que la vente s’est faite conformément au plan de négociation et qu’une partie des avoirs déclarés représente des unités d’actions restreintes non vesties.
James C. Hamilton, Chief Medical Officer von Arrowhead Pharmaceuticals (ARWR), meldete den Verkauf von 15.000 Stammaktien am 09/12/2025 zum Kurs von $30 pro Aktie im Rahmen eines vorab festgelegten 10b5-1 Handelsplans. Nach der Transaktion besitzt er vorteilhafterweise 232.122 Aktien, einschließlich zuvor gemeldeter Aktien unter Restricted Stock Units, von denen einige noch vesting unterliegen.
Das Form 4 legt die Transaktion und die Beziehung der meldenden Person zum Emittenten offen (Beauftragter und Direktors). Die Einreichung klärt, dass der Verkauf gemäß dem Trading Plan erfolgte und dass ein Teil der gemeldeten Bestände unvestete Restricted Stock Units darstellt.
James C. Hamilton، كبير مسؤولي الطب في Arrowhead Pharmaceuticals (ARWR)، أبلغ عن بيع 15,000 سهماً من الأسهم العادية في تاريخ 09/12/2025 بسعر $30 للسهم وفقاً لـ خطة تداول 10b5-1 مُعدة سلفاً. بعد الصفقة يمتلك بشكل مستفيد 232,122 سهماً، بما في ذلك الأسهم المبلغ عنها سابقاً المرتبطة بوحدات أسهم مقيدة، بعضها لا يزال خاضعاً للـ vesting.
يDisclosure Form 4 يسرد الصفقة وعلاقة الشخص المُبلّغ بالمصدر (موظف ومسؤول). التطابق يوضح أن البيع كان وفق خطة التداول وأن جزءاً من الحيازات المبلغ عنها يمثل وحدات أسهم مقيدة غير مُتردة.
James C. Hamilton，Arrowhead Pharmaceuticals（ARWR）首席医疗官，报告于 2025-09-12 以每股 $30 的价格，通过事先设定的 10b5-1 交易计划 出售了 15,000 股普通股。交易后他实际持有 232,122 股，其中包括先前已披露的受限股票单位相关股份，其中部分仍在归属期内。
Form 4 披露了该交易及申报人和发行人之间的关系（高管与董事）。备案指出出售是按照交易计划进行，且所报告的持股部分代表尚未 vest 的受限股票单位。
- Sale conducted under a 10b5-1 trading plan, indicating pre-established execution terms
- Reporting person retains 232,122 shares, including RSUs, showing continued ownership exposure
- Insider sale of 15,000 shares on 09/12/2025 at $30 that reduces the reporting person's immediate stake
Insights
TL;DR: Insider sale executed under a 10b5-1 plan; continued substantial beneficial ownership remains, including RSUs.
The sale of 15,000 shares by the Chief Medical Officer was executed under a documented 10b5-1 plan, which reduces concerns about opportunistic timing by the insider. The filing also confirms continued beneficial ownership of 232,122 shares, some tied to restricted stock units that remain subject to vesting. From a governance perspective, the presence of a formal trading plan and the retention of a significant stake are neutral-to-moderately positive signals about alignment with shareholders.
TL;DR: Officer disposed of a modest number of shares; remaining stake and RSUs keep exposure to company performance.
The disposal of 15,000 shares at $30 per share is a straightforward reporting event. The disclosure that a portion of the 232,122 shares represents restricted stock units highlights that part of the insider’s economic exposure is tied to future vesting. This transaction alone does not provide information on company fundamentals or materially change ownership concentration based on the data provided.
James C. Hamilton, Chief Medical Officer di Arrowhead Pharmaceuticals (ARWR), ha riferito la vendita di 15.000 azioni ordinarie in data 09/12/2025 al prezzo di $30 per azione, nell’ambito di un piano di trading 10b5-1 predefinito. Dopo la transazione detiene beneficially 232.122 azioni, inclusi azioni già riportate legate a unità di azioni vincolate, alcune delle quali restano soggette a vesting.
Il Form 4 rende nota la transazione e la relazione della persona che segnala con l’emittente (Funzionario e Direttore). Il deposito chiarisce che la vendita è avvenuta secondo il piano di trading e che una parte delle partecipazioni riportate rappresenta unità azionarie vincolate non ancora vestite.
James C. Hamilton, Director Médico de Arrowhead Pharmaceuticals (ARWR), informó la venta de 15,000 acciones ordinarias en la fecha 12/09/2025 a $30 por acción, dentro de un plan de negociación 10b5-1 preestablecido. Tras la operación posee beneficiosamente 232,122 acciones, incluidas las acciones previamente reportadas vinculadas a unidades de acciones restringidas, algunas de las cuales siguen sujetas a vesting.
El Formulario 4 divulga la operación y la relación de la persona reportante con el emisor (Funcionarios y Directivos). La presentación aclara que la venta se realizó de acuerdo con el plan de negociación y que una parte de las participaciones reportadas representa unidades de acciones restringidas no vestidas.
James C. Hamilton, Arrowhead Pharmaceuticals(ARWR)의 최고의료책임자, 15,000주 일반주를 2025년 9월 12일에 $30의 주당가로 미리 설정된 10b5-1 거래계획에 따라 매도했다고 보고했습니다. 거래 후 그는 232,122주를 실질적으로 보유하며, 이는 이전에 보고된 제한주식단위와 관련된 주식을 포함하고, 그 중 일부는 아직 vesting 중입니다.
Form 4는 거래와 공시자의 발행자에 대한 관계(임원 및 이사)를 공개합니다. 공시서는 거래가 거래계획에 따라 이루어졌고 보고된 보유분 중 일부가 아직 vesting 중인 제한주식단위를 나타낸다고 명시합니다.
James C. Hamilton, Directeur médical chez Arrowhead Pharmaceuticals (ARWR), a signalé la vente de 15 000 actions ordinaires le 12/09/2025 à 30 $ par action dans le cadre d’un plan de négociation 10b5-1 préétabli. Suite à la transaction, il détient avantageusement 232 122 actions, ce qui inclut des actions déjà signalées liées à des unités d’actions restreintes, dont certaines restent soumises à vesting.
Le Formulaire 4 divulgue la transaction et la relation du déclarant avec l’émetteur (Dirigeant et Administrateur). Le dépôt précise que la vente s’est faite conformément au plan de négociation et qu’une partie des avoirs déclarés représente des unités d’actions restreintes non vesties.
James C. Hamilton, Chief Medical Officer von Arrowhead Pharmaceuticals (ARWR), meldete den Verkauf von 15.000 Stammaktien am 09/12/2025 zum Kurs von $30 pro Aktie im Rahmen eines vorab festgelegten 10b5-1 Handelsplans. Nach der Transaktion besitzt er vorteilhafterweise 232.122 Aktien, einschließlich zuvor gemeldeter Aktien unter Restricted Stock Units, von denen einige noch vesting unterliegen.
Das Form 4 legt die Transaktion und die Beziehung der meldenden Person zum Emittenten offen (Beauftragter und Direktors). Die Einreichung klärt, dass der Verkauf gemäß dem Trading Plan erfolgte und dass ein Teil der gemeldeten Bestände unvestete Restricted Stock Units darstellt.
FAQ
What did ARWR insider James C. Hamilton report on the Form 4?
Was the sale by the ARWR officer part of a trading plan?
How many ARWR shares does James C. Hamilton beneficially own after the sale?
Do the reported holdings include restricted stock units (RSUs)?
What is James Hamilton’s role at Arrowhead Pharmaceuticals?
